UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) (ZIP Code)
Registrant’s telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Directors
On February 14, 2024, the Board appointed Wayne Anderson and Bill Garbarini to the Board of Directors of Evome Medical Technologies Inc. (the "Company"), to serve as directors on the Board until the Company's next annual meeting of shareholders and until their respective successors are duly elected and qualified.
Mr. Anderson was the President and CEO of Ferring Pharmaceuticals USA from 1997 to 2010. Mr. Garbarini has been Chief Executive Officer of Conceivable Life Sciences, a venture backed in-vitro fertilization company since January 2023, and was a Ferring Pharmaceuticals USA executive from 2001 to 2015. Mr. Anderson and Mr. Garbarini will serve on the Audit Committee of the Board, along with Ken Kashkin. With the appointment of the new directors, the total number of directors on the Board will be five.
There are no understandings or arrangements between Mr. Anderson, Mr. Garbarini or any other person and the Company or any of its subsidiaries pursuant to which either Mr. Anderson or Mr. Garbarini was selected to serve as a director of the Company. There are also no transactions involving either Mr. Anderson or Mr. Garbarini that would warrant disclosure pursuant to Item 404 of Regulation S-K.
Item 7.01. Regulation FD Disclosure.
On February 15, 2024, the Company issued a press release announcing, among other things, the appointment of Mr. Anderson and Mr. Garbarini to the Board of Directors. A copy of such press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. This information is furnished pursuant to Item 7.01 "Regulation FD Disclosure," and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | Press Release of Evome Medical Technologies Inc. dated February 15, 2024. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| EVOME MEDICAL TECHNOLOGIES INC. | ||
| Date: February 15, 2024 | By: | /s/ Michael Seckler |
| Name: Michael Seckler | ||
| Title: Chief Executive Officer | ||
EXHIBIT 99.1
Evome Medical Technologies Bolsters Board of Directors with Appointment of Strategic Senior Healthcare Executives Wayne Anderson and Bill Garbarini, Appoints Kenneth Kashkin, MD, as Chairman
New York, New York, February 15, 2024 - Evome Medical Technologies Inc. (the "Company" or "Evome") announces the appointment of two senior healthcare executives to its Board of Directors.
Mr. Wayne Anderson, former President and CEO of Ferring Pharmaceuticals USA, has joined as a non-executive member of the Board of Directors.
Mr. Bill Garbarini, a former Ferring Pharmaceuticals USA executive and current COO of Conceivable Life Sciences, a venture backed in-vitro fertilization company, will also join as a non-executive member of the Board of Directors.
In addition, Kenneth Kashkin, MD, has been appointed Chairman of the Board of Directors. Dr. Kashkin is Board Certified in Internal Medicine, Neurology & Psychiatry with training at, and serving on, the faculties of the University of California, Los Angeles (UCLA) and Yale University Schools of Medicine. He has led development at divisions of Bayer, Abbott, Knoll/BASF Pharma and Baxter.
"Now that we have successfully executed on our turnaround plan, I am pleased to have Wayne and Bill join the Board," said Mike Seckler, CEO of Evome. "I worked with both of these talented and successful healthcare executives for many years while at Ferring and I am eager to benefit from their valuable guidance and expertise, particularly in the realms of product launch and commercialization. Dr. Kashkin's contributions will play a crucial role in advancing our innovation and development strategies, aligning with our vision to democratize our Biodex Brands. I can now say we have completed all of the necessary steps to transform our company. We have driven revenue growth, developed new products, cut costs and restructured our debt. The final step was to add some seasoned talent to our Board to assist us in driving shareholder value."
For more information please contact:
Mike Seckler
Chief Executive Officer
Tel: 1 (800) 760-6826
Email: info@evomemedical.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Document and Entity Information Document |
Feb. 14, 2024 |
|---|---|
| Document Information [Line Items] | |
| Document Type | 8-K |
| Document Creation Date | Feb. 14, 2024 |
| Document Period End Date | Feb. 14, 2024 |
| Amendment Flag | false |
| Entity Registrant Name | Evome Medical Technologies Inc. |
| Entity Address, Address Line One | 49 Natcon Dr |
| Entity Address, City or Town | Shirley |
| Entity Address, State or Province | NY |
| Entity Address, Country | US |
| Entity Address, Postal Zip Code | 11967 |
| Entity Incorporation, State Country Name | A1 |
| City Area Code | 800 |
| Local Phone Number | 760-6826 |
| Entity File Number | 333-255642 |
| Entity Central Index Key | 0001617765 |
| Entity Emerging Growth Company | true |
| Entity Tax Identification Number | 00-0000000 |
| Entity Ex Transition Period | false |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |